European Launch Management

The number and share of international biotechs as well as European and Global specialty pharma companies launching innovative drugs in Europe has been increasing for years, now making up almost half of all product launches. With its decades of experience in working for TOP Pharma companies, IGES Pharma has accompanied this industry trend and developed a tailored set of services and processes specifically for clients that operate very lean market access structures in Europe and its key markets.

IGES Pharma can act as a fully integrated market access function to comprehensively handle all market access processes involved with launching assets into key European markets. From strategic planning to launch sequencing, from data analysis to health economics and HTA submissions, from KOL management to formulary decisions and P&R negotiations – IGES puts its experience to work for our clients so they can focus on making the key decisions and shaping the commercial strategy.